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This pilot study investigated the effectiveness of Mindfulness-Based Cognitive Therapy (MBCT), a treat-
ment combining mindfulness meditation and interventions taken from cognitive therapy, in patients
suffering from chronic-recurrent depression. Currently symptomatic patients with at least three previous
episodes of depression and a history of suicidal ideation were randomly allocated to receive either MBCT
delivered in addition to treatment-as-usual (TAU; N¼ 14 completers) or TAU alone (N¼ 14 completers).
Depressive symptoms and diagnostic status were assessed before and after treatment phase. Self-
reported symptoms of depression decreased from severe to mild levels in the MBCT group while there
was no signiﬁcant change in the TAU group. Similarly, numbers of patients meeting full criteria for
depression decreased signiﬁcantly more in the MBCT group than in the TAU group. Results are consistent
with previous uncontrolled studies. Although based on a small sample and, therefore, limited in their
generalizability, they provide further preliminary evidence that MBCT can be used to successfully reduce
current symptoms in patients suffering from a protracted course of the disorder.
 2009 Elsevier Ltd. Open access under CC BY license.Introduction
In a signiﬁcant number of those affected, Major Depression
follows a protracted lifetime course with patients suffering from
either full episodes or sub-syndromal levels of symptoms over
considerable amounts of time (Kessing, Hansen, & Andersen, 2004;
Solomon et al., 2000). While views of depression often stress its
episodic nature, it has also become clear that in many cases,
patients do not recover fully from episodes but continue to show
residual symptoms, which themselves have been found to be an
important predictor of relapse (Judd et al., 1998; Paykel et al., 1995;
Pintor, Gasto, Navarro, Torres, & Fananas, 2003; Pintor, Torres,
Navarro, Matrai, & Gasto, 2004). In particular, after severe episodes,
sub-syndromal levels of depression are common and persistent
(Kennedy, Abbott, & Paykel, 2004). In other patients, symptoms
remain relatively stable at the level of full episodes over periods of
more than 24 months (Mueller et al., 1996). Recent research has
indicated that regardless of their presentation, i.e., whether
patients continue to suffer from syndromal levels of the disorder or
ﬂuctuate between syndromal and sub-syndromal levels, chronic: þ44 1865 793101.
(T. Barnhofer).
igny Park, London SE5 8AF.
 license.forms of depression are broadly homogeneous with regard to both
their clinical and etiological features, while, at the same time,
differing in important regards from episodic forms of the disorder
(McCullough et al., 2003). For example, individuals suffering from
chronic forms of depression have been found to be more likely to
have a familial history of chronic depression (Klein et al., 1995), to
be more likely to have suffered from early adversity (Lizardi et al.,
1995), to be more likely to suffer from high levels of chronic stress
(Klein, Taylor, Dickstein, & Harding, 1988; Ravindran, Grifﬁths,
Waddell, & Anisman, 1995) and neuroticism (Hirschfeld, Klerman,
Andreasen, & Clayton, 1986; Weissman, Prusoff, & Klerman, 1978),
and to be more likely to suffer from co-morbid disorders, particu-
larly personality (Garyfallos et al., 1999; Pepper et al., 1995) and
anxiety disorders (Weissman, Leaf, Bruce, & Florio, 1988). Most
importantly, chronic forms of depression have been found to be
signiﬁcantly less responsive to treatment (Thase, Reynolds, Frank, &
Simons,1994) with reports of rates of responders to single modality
treatments in trials aimed at chronic depression or based on
samples with highly recurrent forms of depression at about 50%
(DeRubeis et al., 2005; Keller et al., 2000). There is, thus, an
important need for further reﬁnement of treatments for those who
have developed a more protracted course of the disorder.
Mindfulness-Based Cognitive Therapy (MBCT; Segal, Williams,
& Teasdale, 2002) is a treatment programme that was speciﬁcally
designed to address latent vulnerability in depression. It combines
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cognitive therapy for acute depression and is delivered in a group
setting. The rationale of the treatment is based on ﬁndings from
cognitive research on vulnerability that has linked relapse to
mood-related reactivation of negative thinking patterns (Lau,
Segal, & Williams, 2004; Scher, Ingram, & Segal, 2005) and mal-
adaptive ways of responding to negative cognitions and emotions
such as rumination (e.g., Watkins, 2008), thought suppression
(Wenzlaff & Bates, 1998) and experiential avoidance, i.e., an
unwillingness to remain in contact with one’s private experiences,
leading to attempts at altering experience so that it is less aversive
(Hayes et al., 2004). Through the use of mindfulness meditation,
participants are taught to develop their ability to recognize and
disengage from maladaptive forms of negative automatic and
repetitive thinking. In two randomized controlled trials (RCTs), in
which previously depressed patients were followed up over
a period of one year following the treatment phase, MBCT has
been found to reduce risk of relapse by approximately half in
patients with three or more previous episodes of depression (Ma
& Teasdale, 2004; Teasdale et al., 2000). A recent study has found
MBCT to be as effective in reducing relapse over a follow-up
period of 15 months as maintenance therapy with antidepressants
(Kuyken et al., 2008).
Each of these three previous RCTs of MBCT studied only
patients who were in remission or recovery. The use of MBCT in
current depression had been discouraged because it was unclear
whether the cognitive demands of a regular meditation practice
would exceed the restricted capacities of depressed patients.
However, as factors speciﬁcally addressed by MBCT are likely to
play an important role not only in recurrence but also in the
maintenance and persistence of depression, interest in applying
MBCT to a wider range of patients has recently increased. In
chronically depressed patients, maladaptive thinking patterns
such as rumination and experiential avoidance are likely to have
acquired a habitual nature, and mental training using mindfulness
meditation may hold particular promise in reversing such
tendencies. In line with this, there are now a number of reports
that suggest that MBCT can successfully reduce symptoms in
currently depressed patients (Finucane & Mercer, 2006; Kingston,
Dooley, Bates, Lawler, & Malone, 2007), with two of the studies
showing effects in patients who had been found to be resistant to
established forms of treatment (Eisendrath et al., 2008; Kenny &
Williams, 2007). However, with the exception of the study by
Kingston et al. which only included participants with residual
symptoms, all of these reports are based on uncontrolled pre–
post-comparisons.
The purpose of the current study was to carry out a preliminary
study to investigate the effects of MBCT in patients suffering from
chronic forms of depression using a randomized controlled design
with blind assessments. We compared the immediate effects of
MBCT delivered in addition to treatment-as-usual (TAU) to TAU
alone. At this stage of knowledge and given the high vulnerability of
this group, we offered MBCT to the TAU group as soon as the post-
treatment assessments were complete, effectively establishing
a waitlist condition. The study focused on patients with a history of
suicidality in the past, a group in which cognitive vulnerability has
been found to be particularly pronounced (Williams, Barnhofer,
Crane, & Beck, 2005; Williams, Van der Does, Barnhofer, Crane, &
Segal, 2008), thus, addressing themost severe end of the depressive
spectrum. We hypothesized that participants in the MBCT condi-
tion would show signiﬁcant decreases in severity of depressive
symptoms, while no such changes were expected in the TAU group,
and that number of responders at the end of the treatment phase
would be signiﬁcantly higher in the MBCT than in the TAU
condition.Method
Participants
The study had received full approval by the Mid and South
Buckinghamshire Local Research Ethics Committee (Ref: 07/Q1607/
2). Participants were recruited through local media advertisements
and posters as well as referrals from local mental health practi-
tioners. Interested individuals were screened in a telephone inter-
view and those indicating current presence of core symptoms of
depression (feeling sad or depressed, or loss of interest) and
a history of chronic or recurrent depression with suicidal ideation
were invited for an assessment session at the Department of
Psychiatry. In this session, eligibility was assessed using the
Structured Clinical Interview for DSM-IV-TR Axis I (SCID; First,
Gibbon, Spitzer, & Williams, 2002) and the DSM-IV module for
Borderline Personality Disorder, in order to assess presence of
habitual self-harming, administered by a trained clinical research
psychologist. Inclusion criteria were (a) a history of at least three
previous episodes of Major Depression or Chronic Depression, i.e.,
a full episode of Major Depression lasting for at least two years, (b)
a current diagnosis of Major Depression or presence of residual
symptoms following a full episode, deﬁned as either meeting DSM-
IV criteria for only four instead of at least ﬁve symptoms of
depression over the last two weeks or suffering from ﬁve or more
symptoms for at least half of the days, if symptoms had not been
present formost of the days over the past twoweeks, (c) a history of
suicidal ideation (including thoughts of methods of suicide) or
suicidal behavior, (d) absence of current mania or hypomania,
psychosis, obsessive-compulsive disorder, eating disorder, perva-
sive developmental disorder or habitual self-harming, substance
abuse or dependence that would signiﬁcantly interfere with the
ability to engage in meditation, (e) adequate written and spoken
English to complete all study measures, (f) not currently in indi-
vidual or group psychotherapy and no current ongoing meditation
practice, and (g) age between 18 and 65. In addition to our own
assessments, we required written conﬁrmation from the partic-
ipant’s GP that there was no contraindication for him or her to take
part in the study.
A total of 90 individuals made an initial contact in response to
information regarding the study, of which 43 did not participate.
The main reasons for people who had made an initial contact not to
participate were (a) they were not interested after hearing more
about the study or had other commitments that would have
interfered with participation in the study (14, 32%), (b) the research
team was unable to contact them for a telephone interview after
their initial contact (7, 16%), and (c) they did not meet criteria for
the study (22, 53%; six current level of depression below inclusion
criteria, three not suicidal in the past, four current mania or
hypomania, three current eating disorder, two current psychotic
symptoms, one severe habitual self-harm, three older than 65 years
of age). Of the 47 participants, who were invited for an interview at
the Department of Psychiatry, 13 were found not to be eligible
(three current level of depression below inclusion criteria, four
habitual self-harming, one pervasive developmental disorder, one
mania, one hypomania, one alcohol dependence, one eating
disorder, one would not have been available at time of classes).
Three further participants were lost following the interview: one
withdrew before randomization and before completing any
measures, for one participant consent from their GP could not be
obtained, and with one participant who, during the interview, had
displayed signiﬁcant deﬁcits in orientation, memory and attention,
the origin of which was currently unknown but seemed likely to be
neurological, it was mutually decided that participation in the
classes was too demanding and, therefore, contraindicated. This left
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those who had been randomized, three participants, two from the
MBCT group and one from the TAU group, dropped out before the
post-treatment phase assessments. Full data sets were, therefore,
available for N¼ 14 participants allocated to MBCT and N¼ 14 to
TAU. The ﬂow of the participants through the trial is depicted in
Fig. 1.
In order to test the feasibility of MBCT for chronically depressed
patients at this early stage of development, the study was restricted
to only one cohort. Previous pre–post-comparisons of MBCT in
currently depressed patients had produced effects sizes of d¼ 1.00
(Eisendrath et al., 2008, Kenny & Williams, 2007). In order to ﬁnd
effects of a similar size with power of 0.80 at an a-level of 0.05, we
would have had to recruit 16 participants into each group.
However, given that effect sizes in a control group design are likely
to be smaller, the current study was underpowered.
Characteristics of the two groups are summarized in Table 1
along with the results of t-tests for continuous variables and c2-
tests for binary variables. The two groups were comparable in their
sociodemographic characteristics including age, gender distribu-
tion, their relationship status, years of education and employment.Initial Contact and Scre
Assessed for Eligib
Enrollmen
Allocated to TAU (n = 15) Allocatio
Randomiza
Treatment PWithdrew (n = 1)
Post Assess
Participated in Post Assessment
(n = 14)
Analysis
ITT analyses (n = 15)
Per-protocol analyses (n = 14)
Fig. 1. Flowchart depicting passage oMost participants were middle-aged, about two thirds were
women and about half of the participants were married or co-
habiting.
Overall, the sample was characterized by a protracted course of
the disorder with early onset and high rates of chronicity and
recurrence. There were signiﬁcantly more individuals who were
classiﬁed as suffering from a chronic full episode in the TAU group.
However, the two groups were comparable with regard to both the
average duration of the last episode of depression, when residual
symptoms were taken as part of an ongoing episode, i.e., length of
time until full recovery, as well as the overall duration of the
disorder, i.e., number of months that individuals had suffered from
the disorder. About two thirds of both groups were in full episode at
baseline while the remaining third suffered from symptoms at sub-
threshold levels after having been in a full episode. None of the
participants, therefore, were in remission, so nonewould have been
entered into any of the three previous RCTs of MBCT (Kuyken et al.,
2008; Ma & Teasdale, 2004; Teasdale et al., 2000).
About 80% of participants had previously received treatment
with antidepressant medication and about 60% were taking anti-
depressants when the trial started: four participants tricyclicening (n = 90)
Excluded (n = 43)
Not interested/eligible
ility (n = 47)
t
Allocated to MBCT (n = 16)n
tion
Excluded (n = 16)
Not meeting inclusion criteria (n = 13)
Refused to participate (n = 1)
Other reasons (n = 2)
hase Discontinued intervention (n = 2)
ment
Participated in Post Assessment
(n = 14)
ITT analyses (n = 16)
Per-protocol analyses (n = 14)
f participants through the trial.
Table 1
Sample characteristics of the MBCT (N¼ 14) and TAU (N¼ 14) groups.
MBCT TAU Test-statistic p
Age M (SD) 42.07 (11.34) 41.79 (9.52) t (26)¼ 0.07 ns
Gender (female/male) 10/4 9/5 X2¼ 0.16 ns
Married/co-habiting n (%) 7 (50) 7 (50) c2 (N¼ 28)¼ 0.00 ns
Years of education M (SD) 16.38 (3.04) 15.21 (3.19) t (25)¼ 0.97 ns
Employed n (%) 13 (92) 11 (78) c2 (N¼ 28)¼ 1.16 ns
Current MDD (full episode/residual symptoms) 10/4 11/3 c2 (N¼ 28)¼ 0.19 ns
Age of Onset M (SD) 20.57 (7.64) 23.21 (11.68) t (26)¼ 0.71 ns
Number of episodes Mde (range) 4 (1–50) 3 (1–6) Mann-Whitney U¼ 58 ns
Number of episodes M (SD) 7.76 (12.9) 3.07 (1.89) t (24)¼ 1.29 ns
Chronic Depression n (%)a 7 (50) 12 (85) c2 (N¼ 28)¼ 4.09 0.04
Duration of last episode in months M (SD) 87.92 (149.80) 51.07 (41.20) t (26)¼ 0.88 ns
Total duration in months M (SD) 116.50 (141.32) 87.23 (43.23) t (23)¼ 0.71 ns
History of manic or hypomanic episode n (%) 1 (7) 1 (7) c2 (N¼ 28)¼ 0.00 ns
Co-morbid anxiety disorder n (%) 4 (28) 6 (42) c2 (N¼ 28)¼ 0.62 ns
Co-morbid somatoform disorder n (%) 2 (14) 0 (0) c2 (N¼ 28)¼ 2.15 ns
Co-morbid axis I disorder (one or more) n (%) 6 (42) 6 (42) c2 (N¼ 28)¼ 0.00 ns
Previous suicide attempt n (%) 4 (28) 4 (28) c2 (N¼ 28)¼ 0.00 ns
Previous psychotherapy or counseling n (%)b 10 (71) 11 (79) c2 (N¼ 28)¼ 0.19 ns
Previous CBT n (%) 7 (50) 8 (57) c2 (N¼ 28)¼ 0.14 ns
Past treatment with antidepressant medication n (%) 11 (79) 12 (86) c2 (N¼ 28)¼ 0.24 ns
Current treatment with antidepressant medication n (%) 9 (64) 8 (57) c2 (N¼ 28)¼ 0.15 ns
a Note. Participants with episodes of MDD lasting at least two years or recurrent depression without full inter-episode recovery over an equivalent period of time.
b More than 5 sessions.
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three serotonine–norepinephrine reuptake inhibitors, two tetra-
cyclic antidepressants, and one an atypical antipsychotic as their
main medication. The two groups did not differ signiﬁcantly with
regard to the numbers of participants who were currently taking
antidepressant medication.
More than two thirds of the participants had previously received
some form of psychotherapy or counseling over at least ﬁve
sessions and more than half of them had previously received CBT
with rates of those who had previously received psychological
treatment comparable in the two groups.
Procedure
All participants provided written informed consent prior to the
start of the research assessments. They took part in two sessions
both before and after the treatment phase at the Department of
Psychiatry, Warneford Hospital. Pre-assessments were conducted
within 2 ½ months of the start of the treatment phase, from the
start of recruitment in mid February until end of April 2007 (mean
number of days between ﬁrst assessment and start of treatment
phase: TAU: M¼ 49.00, SD¼ 17.27; MBCT: M¼ 40.79, SD¼ 15.17, F
(1, 26)¼ 1.78, p¼ 0.19), and post-assessments took place within 1
month after the end of the treatment phase, from the beginning to
end of July 2007 (mean number of days from end of treatment
phase to ﬁrst post-assessment: TAU: M¼ 12.00, SD¼ 7.61; MBCT:
M¼ 11.64, SD¼ 6.24; F (1, 26)¼ 0.01, p¼ 0.89). During the ﬁrst of
the two sessions, the structured clinical interview was conducted
and participants completed several self-report questionnaires as
well as a number of cognitive tasks. Assessors did not have access to
any information about the participants that related to their group
status and participants were explicitly instructed not to give any
hints regarding their group membership during the post-assess-
ment interview. The second session was used to assess EEG
parameters of brain functioning, the results of which are not
reported here. Participants were randomly allocated to either MBCT
or TAU after eligibility was ascertained in the ﬁrst assessment
session pre treatment. Randomization was conducted using sealedenvelopes prepared by a statistician from outside of the research
team using a computer generated randomization sequence (blocks
of 4, no stratiﬁcation) that remained concealed until assignment to
the groups. Participants were informed about assignment by the
research administrator coordinating the study while interviewers
and assessors remained blind.
Measures
Structured Clinical Interview for DSM-IV-TR (SCID; First et al., 2002)
The Research Version of the Structured Clinical Interview for
DSM-IV-TR Axis I Disorders and the Borderline Personality Disorder
Module of the Structured Clinical Interview for DSM-IV Axis II were
used to assess current and past diagnostic status at entry into the
study. In order to facilitate tracking of more complex courses of
depression, the interviewwas supplemented with a visual grid that
served as a timeline on which the beginning and end of previous
episodes of depression were marked. Post-treatment assessment
interviews used the mood disorders module of the SCID only and
focused on the time since the ﬁrst interview in order to assess any
change in diagnostic status.
Beck Depression Inventory-II (BDI-II; Beck, Steer, & Brown, 1996)
Self-reports on the BDI-II were used to measure severity of
current depressive symptoms pre- and post-treatment. The BDI-II
contains 21 statements, assessing symptoms over the preceding
two weeks. Beck, Steer, and Brown report excellent internal
consistency in both patient and student samples.
Beck Scale for Suicide Ideation (BSS; Beck & Steer, 1991)
The BSS was used to measure presence and severity of suicidal
ideation. The self-report questionnaire comprises 21 groups of
statements including a screening section that contains ﬁve items
speciﬁcally designed to identify suicidal ideation in active or
passive form. Individuals whose answers in the screening section
indicate suicidal ideation are asked to answer 14 further items
assessing the extent of their wish to die. Two further items ask for
information about previous suicide attempts. Analyses reported
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presence of suicidal ideation before and after treatment in both
groups. Internal consistency of the screening items in our sample
was a¼ 0.87 at pre-assessment and a¼ 0.90 at post-assessment.Treatment
Participants of both groups were encouraged to continue any
current medication and to attend appointments with their mental
health practitioners or other services over the treatment phase as
they would have done otherwise. MBCT and TAU participants were
entered into the study only if they did not currently receive any
form of individual psychotherapy and were asked not to start one
during the time of the study. TAU participants were, additionally,
asked not to start a regular meditation practice during the time of
the study.
Before the start of the treatment phase participants in the MBCT
group were invited for a pre-class interview with the therapist to
prepare them for the course while participants in the TAU group
met with the research coordinator to discuss further procedures
until the start of their treatment after the waiting period. TheMBCT
treatment followed the manual by Segal et al. (2002) with some
minor alterations to address suicidality and presence of acute
symptoms, i.e., introduction of crisis plans and cognitive compo-
nents addressing suicidal cognitions and hopelessness. Handouts
and protocol sheets for home practice were taken from the manual
without major alteration. Participants in the MBCTconditionmet in
a group of, initially, 16 patients for eight weekly classes of 2 h
duration in June and July 2007. In addition to the classes, they were
asked to engage in homework including regular meditation or
mindful movement practice and various other related exercises for
about an hour per day for six days a week. The classes were led by
a fully-qualiﬁed CBT therapist who had trained in Mindfulness-
Based Stress Reduction through an internship at the Center for
Mindfulness in Medicine, Health Care and Society at the University
of Massachusetts, Worcester, Medical Center (TB), and who deliv-
ered the treatment under regular supervision of JMGW, one of the
developers of the programme, who monitored adherence to the
treatment protocol.
An overviewof services and treatments participants used as part
of their TAU is given in Table 2. Over the course of the treatment
phase, seven of the participants in the TAU group changed their
medication: two participants who had not been on antidepressants
at the start of the study resumed taking antidepressant medication,
two participants changed their medication to include a new,
additional antidepressant, one increased the dosage of the current
medication, and two lowered the dosage of their medication. In the
MBCT group, two participants changed medication over the course
of the treatment phase, one went off their medication and one
increased the dosage of their medication. Differences in number of
participants in the two groups who changed medication were
marginally signiﬁcant, Fisher’s Exact Test, p¼ 0.052. However, asTable 2
Number (and percentages) of participants in the MBCT (N¼ 14 completers) and TAU
(N¼ 14 completers) receiving particular services and treatments during the treat-
ment phase.
MBCT TAU Fisher’s Exact
Test p
Changed antidepressant medication 2 (14) 7 (50) 0.052
Received psychological intervention 4 (28) 6 (42) ns
Visited GP regarding depression 8 (57) 7 (50) ns
Received visit by psychiatric nurse 4 (28) 4 (28) ns
Use of self-help (books etc.) 6 (42) 6 (42) nsthis difference was due mostly to increased use of antidepressants
in the TAU group, any effect on outcome measures would have
worked against our hypotheses and change in medication was,
therefore, not used as a covariate in outcome analyses. Groups were
comparable with regard to use of services in all other categories
assessed. Psychological treatments were used by six of the partic-
ipants in the TAU group (one attended a single follow-up
appointmentwith their GP, one a single appointmentwith amental
health nurse, one participant received two sessions of counseling,
and two had a number of appointments with their psychiatrist that
included CBT-type interventions) and four of the participants in the
MBCT group (three participants had appointments with their
counselor, one participant one appointment, one participant two
appointments, and one participant four appointments; one other
participant in this group started participating in therapeutic group
meetings in a religious context towards the end of the treatment
phase). Seven of the participants in the TAU group and eight of the
participants in the MBCT group had appointments with their GP
related to their depressive disorder, one or more times, during the
treatment phase, and in both groups, four of the participants had
one or more visits from a psychiatric nurse that was related to their
depressive disorder. Six of the participants in each group reported
looking into some form of self-help approach during the treatment
phase, reading books about depression and mental health or
searching for related information on the internet.
Outcome measures
Analyses of outcome focussed on changes in level of depressive
symptoms as assessed by self-reports on the BDI-II and changes in
diagnostic status as assessed by SCID interview conducted by blind
assessors. Treatment response was deﬁned by combination of two
criteria: a 50% reduction in BDI-II scores from pre- to post-treat-
ment together with a post-treatment BDI-II score of 13 or below,
which is deﬁned as the threshold level for mild depressive
symptoms.
Results
Treatment acceptance
Participants who completed the MBCT treatment attended an
average of M¼ 6.14 (SD¼ 1.51) classes. Homework records indi-
cated that they had practiced meditation or yoga on an average of
4.98 days out of the six days they had been asked to practice
between sessions for about an hour per day. There were no adverse
events that were deemed to be related to the treatment. One
participant in the MBCT group contacted the therapist during
a suicidal crisis and after crisis intervention was referred to their
psychiatrist. This patient continued to participate in the classes and
assessments.
Changes in severity of depressive symptoms
Intention-to-treat analyses were conducted ﬁrst, including all
participants whowere randomized into the study. For this purpose,
the BDI-II scores of those three participants whowithdrew from the
study after randomization were carried forward, from pre- to post-
assessment. Carrying forward the baseline scores of those who
withdraw is a conservative approach of data imputation since it
assumes no change in these participants. Resulting average severity
of symptoms as measured with BDI-II wasM¼ 29.36 (SD¼ 9.66) at
pre-assessment and M¼ 17.62 (SD¼ 10.94) at post-assessment in
the MBCT group, andM¼ 31.32 (SD¼ 10.79) at pre-assessment and
M¼ 28.86 (SD¼ 12.97) at post-assessment in the TAU group. A 2
Table 3
Numbers of Participants meeting DSM-IV criteria for Major Depression at pre- and
post-assessment in the MBCT (N¼ 14 completers) and TAU groups (N¼ 14
completers).
Post-assessment
MDD No MDD
Pre-Assessment MBCT MDD 3 7
No MDD 1 3
TAU MDD 9 2
No MDD 0 3
Note. MDD¼major depressive disorder.
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measures ANOVA of BDI-II scores with time as within- and group as
between-subjects factor yielded a signiﬁcant main effect of time, F
(1, 29)¼ 13.42, p¼ 0.001, partial h2¼ 0.32, that was qualiﬁed by
a signiﬁcant time by treatment interaction, F (1, 29)¼ 5.74, p¼ 0.02,
partial h2¼ 0.17,MI  J¼ 11.74, SE¼ 2.69, p< 0.001, partial h2¼ 0.39,
95% CI: lower bound¼3.23, upper bound¼ 8.15, in the MBCT
group andMI  J¼ 2.45, SE¼ 2.78, p¼ 0.38, partial h2¼ 0.02, 95% CI:
lower bound¼ 6.23, upper bound¼ 17.25, in the TAU group. This
interaction remained signiﬁcant when duration of the last episode
was taken into account as a covariate, F (1, 28)¼ 5.01, p¼ 0.03.
Second, we analysed the per-protocol sample. This showed
average BDI-II scores ofM¼ 30.35 (SD¼ 9.9) at pre-assessment and
M¼ 16. 92 (SD¼ 11.53) at post-assessment in the MBCT group, and
M¼ 32.06 (SD¼ 10.80) at pre-assessment and M¼ 29.42
(SD¼ 13.27) at post-assessment in the TAU group. The 2 (time: pre
versus post) 2 (group: MBCT versus TAU) repeated measures
ANOVA of BDI-II scores with time as within- and group as between-
subjects factor yielded a signiﬁcant main effect, F (1, 26)¼ 15.37,
p¼ 0.001, partial h2¼ 0.37, qualiﬁed by a signiﬁcant group by time
interaction, F (1, 26)¼ 6.9, p¼ 0.014, partial h2¼ 0.21. Bonferroni-
corrected follow-up tests showed the change in symptoms in the
MBCT group to be signiﬁcant, MI  J¼13.42, SE¼ 2.89, p< 0.001,
partial h2¼ 0.45, 95% CI: lower bound¼7.47, upper
bound¼19.37, while change in the TAU group was non-signiﬁ-
cantMI  J¼ 2.63, SE¼ 2.89, p¼ 0.37, partial h2¼ 0.03, 95% CI: lower
bound¼3.38, upper bound¼ 8.58. Again, results remained
statistically signiﬁcant when analyses were re-run with length of
current episode in months as a covariate, F (1, 25)¼ 6.16, p¼ 0.02
for the time by treatment interaction.
Rates of response
Intention-to-treat analyses of treatment responses included
those participants who withdrew from the study following
randomization as non-responders. Using the above described
combined criterion, a reduction in BDI-II score of at least 50% and
a post-treatment BDI-II score of 13 or below, 6 out of the 16
participants randomized to MBCT were classed as responders,
yielding a response rate of 37%. In contrast, in the TAU group, only 1
out of the 15 participants randomized into this group showed
decreases in symptoms that would have fulﬁlled these criteria,
yielding a rate of 6%. A c2-test showed this difference to be
signiﬁcant, c2 (N¼ 31)¼ 4.21, p¼ 0.04.
Analyses based on the per-protocol sample yielded response
rates of 43% (6 out of 14 participants) in the MBCT group and 7% (1
out of 14) in the TAU group. As in the intention-to-treat analysis,
a c2-test showed this difference to be signiﬁcant, c2 (N¼ 28)¼ 4.76,
p¼ 0.02.
Change in diagnostic status
We also analysed changes in numbers of participants who met
criteria for a full episode of Major Depression as assessed by SCID
interview conducted by assessors blind to treatment allocation. For
these analyses, it is important to keep in mind that, as some of the
participants did not meet full criteria for an episode of Major
Depression at entry into the study, diagnostic status can reﬂect
positive change, i.e., changes from diagnostic to non-diagnostic
status, only in a subgroup of participants. Table 3 provides an
overview of numbers of participants meeting full criteria for MDD
at pre- and post-assessment. As all three of the participants who
withdrew over the course of the study did not meet full criteria for
diagnostic status at entry, the below analyses are based entirely on
participants from the per-protocol sample. Of those who had metcriteria for a full episode of depression at entry into the study, 7 out
of 10 participants (70%) in the MBCT group did not meet criteria for
a full episode of Major Depression at post-assessment, while this
was the case for only 2 out of 11 participants (18%) in the TAU group,
Fisher’s Exact Test p¼ 0.03 (Table 3).
Change in suicidal ideation
Changes in suicidal ideation as assessed by self-reports on the
screening items of the BSS were analysed using 2 (time: pre versus
post) 2 (group: MBCT versus TAU) repeated measures ANOVAs.
Neither analyses in the intent-to-treat nor the per-protocol sample
yielded signiﬁcant effects (intent-to-treat sample: time group
interaction, F (1, 29)¼ 0.16, p¼ 0.50; per-protocol sample: time -
 group interaction, F (1, 26)¼ 0.52, p¼ 0.47). In the per-protocol
sample, average BSS screening scores at pre- and post-assessment,
respectively, were M¼ 2.21 (SD¼ 2.45) and M¼ 1.14 (SD¼ 1.79) in
the MBCT group andM¼ 2.78 (SD¼ 2.08) andM¼ 2.42 (SD¼ 2.53)
in the TAU group.
Discussion
The aim of this study was to conduct a preliminary randomized
controlled trial to investigate whether MBCT can successfully
reduce symptoms of depression in currently symptomatic patients
who suffer from a protracted course of the disorder and in whom
spontaneous recovery is relatively unlikely to occur. Previous RCTs
had excluded such patients on the grounds that MBCT might be
inappropriate unless patients were in remission or recovery;
though there had been promising results from uncontrolled trials
(Eisendrath et al., 2008; Finucane & Mercer, 2006; Kenny &
Williams, 2007). Consistent with these studies, our results showed
that treatment with MBCT signiﬁcantly reduced self-reported
symptoms of depression from severe to mild levels, while levels of
depression remained unchanged in the group that received TAU
only. Numbers of patients who met criteria for Major Depression
decreased in the MBCT group but remained in the TAU group.
While the current study extends previous research by using
a randomized controlled design and blind assessments, there are
a number of limitations that need to be taken into account. First of
all, andmost importantly, this study is based on only a small sample
of patients. Because of this, the study is potentially more vulnerable
to spurious effects and generalizability of its ﬁndings is more
uncertain. One potential difﬁculty that comes with small numbers
is that randomization is more likely to fail to produce groups that
are comparable in all important respects. The two groups here
differed with regard to the proportion of participants classiﬁed as
currently being in a full chronic episode of depression as compared
to suffering from residual symptoms following a full episode.
Because of this imbalance, it could be argued that part of the
differential changes in symptoms found may be due to participants
in the TAU group being less likely to show spontaneous recovery
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possibility cannot be completely ruled out, there are several points
that speak against it. First, when length of current episodewas used
as a covariate in analyses of BDI-II changes, results remained
signiﬁcant. Second, previous research on chronic depression has
demonstrated that, while diagnostic systems differentiate between
chronic episodes of depression and recurrent depression without
full inter-episode remission, these two forms share more similari-
ties than there are differences between them in terms of clinical
features and risk factors (McCullough et al., 2003). Consistent with
this, the two groups in our study, although different in terms of
numbers of those suffering from chronic episodes, did not differ in
total length of time they had suffered from depression in their
lifetime nor length of the last episode when ongoing residual
symptoms were taken as part of the episode.
A second important limitation of the study is that the main
ﬁndings regarding severity of depressive symptoms are based on
self-reports, which are amenable to subjective biases. Ideally, these
measures would have been complemented by observer-rated
measures of symptom severity. However, while there was no such
measure for symptom severity, the study did include structured
interviews to assess diagnostic status before and after the treat-
ment phase. Although comparisons of numbers of participants who
qualiﬁed for a full diagnosis of depression were restricted because
some of the participants did not meet full criteria for a diagnosis of
Major Depression at pre-assessment, analyses yielded signiﬁcant
effects indicating stronger decreases in number of patients meeting
full criteria in the MBCT group (70% no longer meeting diagnostic
criteria) than in the TAU group (18%).
The current sample was characterized by a protracted course of
the disorder and all of the participants had suffered from suicidal
ideation in the past. Both established psychotherapeutic and
pharmacological treatments have been found to fail to help
a signiﬁcant number of these patients. For example, in a large
recent study of cognitive therapy for severe depression, where
many of the patients included reported a recurrent or chronic
course of the disorder, rates of response were 58% (DeRubeis et al.,
2005). A large study investigating a treatment speciﬁcally designed
for chronic depression, the Cognitive Behavioral-Analysis System of
Psychotherapy (CBASP), found satisfactory responses after 16–20
sessions of individual therapy in 48% of patients, a rate that
increased to 73% in those who received both CBASP treatment in
addition to psychopharmacological treatment with the antide-
pressant nefazodone (Keller et al., 2000). Given the relatively low
intensity of MBCT with only eight weekly sessions and the
economic advantage of the treatment being delivered in groups,
the rates of response found in our study can be judged as generally
encouraging. Direct comparisons of rates of response between this
and other studies need to take into account that the current study
used a combined criterion requiring both severity levels below
a certain threshold level and percentage change as compared to use
of a threshold level only.
Despite the fact that, initially, the developers of MBCT had
cautioned against its use in currently depressed patients, rates of
attendance at classes and the data from participants’ records of
homework practice suggest that the treatment is both acceptable
and manageable for this group. These data were in line with the
clinical impressions from the classes. Because of their current
symptoms, we had expected that patients would encounter more
negative content during their meditations and one particular
concern had been that, especially in the early stages of the treat-
ment, participants might get easily overwhelmed by this negative
content and ﬁnd it more difﬁcult to use the meditation techniques
to their advantage. In cases where this seemed to be a problem, we
offered participants the opportunity to choose their home practicemore ﬂexibly, and, when needed, to use practices that provided
particularly tangible anchors for their attention such as sensations
of the body during yoga stretches or the sensations of the breath
during sitting meditations. Another variation offered to partici-
pants was to experiment, in sitting meditations, with opening their
eyes at times when they found content to be overwhelming and to
use this technique to approach difﬁcult content in a stepwise
manner. Clinical impressions suggested that only a small number of
patients required and made use of these variations of the standard
practice.
While results showed signiﬁcant decreases in severity of
depressive symptoms, we did not ﬁnd signiﬁcant changes in
suicidal ideation. In part, this may be due to lack of power for
detecting such differences as a large number of patients entered the
study with relatively low levels of suicidal ideation. Taken as they
are, though, these ﬁndings suggest the need to address suicidal
thinking in even more detail. Possible additions could, for example,
include a psychoeductional component on the impact of suicidal
imagery and the immediacy with which such imagery can occur
and impact. Recent research has suggested that suicidal patients,
when at their most despairing, often suffer from intrusive mental
images of suicide and that the frequency and subjective reality of
such images is signiﬁcantly related to severity of suicidal ideation
(Holmes, Crane, Fennell, & Williams, 2007). Yet, available treat-
ments so far have not included a speciﬁc focus on this aspect of
psychopathology.
Research on the effects of meditation has been growing over
the recent years and studies suggest that regular meditation
practice can produce lasting effects on attention, executive func-
tioning (Lutz, Slagter, Dunne, & Davidson, 2008; Slagter et al.,
2007; Tang et al., 2007) and emotion regulation (Nielsen &
Kaszniak, 2006). Systematic training of these functions through
meditation may be particularly helpful in patients suffering from
chronic depression where vulnerability processes such as rumi-
nation are likely to have acquired a habitual and automatic char-
acter and are more likely to occur when cognitive control is
undermined. This small-scale randomized controlled trial
comparing MBCT to TAU represents a logical next step in testing
the application of MBCT in chronic depression, following positive
reports from clinical audits. Altogether, the ﬁndings provide
preliminary evidence suggesting that using mindfulness medita-
tion in the treatment of chronic or recurrent depression is feasible
and may provide a valuable addition to already established
interventions. Further research into the effects of mindfulness
meditation will help to tailor the MBCT program more speciﬁcally
to the needs of this group. The focus here was on immediate
effects and future studies need not only replicate the current
ﬁndings but should also use more extensive follow-ups given the
high risk of relapse in the histories of these patients as well as
active treatment comparisons in order to control for unspeciﬁc
effects of the MBCT training.Acknowledgements
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